Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) Ratios

― Followers

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Ratios

KR:950210's free cash flow for Q4 2024 was ₩-2.27. For the 2024 fiscal year, KR:950210's free cash flow was decreased by ₩ and operating cash flow was ₩-0.96. See a summary of the company’s cash flow.

Ratios	TTM	Jun 25	Jun 23	Jun 22	Jun 22
Liquidity Ratios
Current Ratio	―	1.27	1.72	7.45	2.31
Quick Ratio	―	1.11	1.59	7.40	2.26
Cash Ratio	―	0.70	1.50	6.43	0.93
Solvency Ratio	―	0.19	-0.08	-2.97	0.15
Operating Cash Flow Ratio	―	-0.33	-0.33	-1.10	-0.45
Short-Term Operating Cash Flow Coverage	―	-0.49	-1.00	-28.69	-1.83
Net Current Asset Value	₩ ―	₩ -27.20B	₩ 54.13B	₩ 241.69B	₩ 116.11B
Leverage Ratios
Debt-to-Assets Ratio	―	0.19	0.13	<0.01	0.12
Debt-to-Equity Ratio	―	0.35	0.20	<0.01	0.19
Debt-to-Capital Ratio	―	0.26	0.17	<0.01	0.16
Long-Term Debt-to-Capital Ratio	―	0.07	0.08	0.00	0.10
Financial Leverage Ratio	―	1.81	1.62	1.16	1.65
Debt Service Coverage Ratio	―	0.28	-0.57	-128.29	0.29
Interest Coverage Ratio	―	-8.83	-8.48	-6.30K	1.09
Debt to Market Cap	―	0.16	0.17	<0.01	0.15
Interest Debt Per Share	―	2.53K	1.62K	71.02	1.45K
Net Debt to EBITDA	―	0.86	4.18	1.28	-3.69
Profitability Margins
Gross Profit Margin	―	-167.77%	-76.74%	0.00%	79.03%
EBIT Margin	―	80.62%	-6868.65%	0.00%	-707.84%
EBITDA Margin	―	232.80%	-4505.69%	0.00%	6496.03%
Operating Profit Margin	―	-470.14%	-9111.19%	0.00%	639.51%
Pretax Profit Margin	―	27.38%	-7936.63%	0.00%	-1294.78%
Net Profit Margin	―	155.64%	-4777.60%	0.00%	10855.89%
Continuous Operations Profit Margin	―	29.12%	-7995.94%	0.00%	-1766.40%
Net Income Per EBT	―	568.42%	60.20%	100.38%	-838.43%
EBT Per EBIT	―	-5.82%	87.11%	177.28%	-202.47%
Return on Assets (ROA)	―	3.00%	-4.63%	-42.31%	2.37%
Return on Equity (ROE)	―	5.45%	-7.50%	-49.18%	3.90%
Return on Capital Employed (ROCE)	―	-11.65%	-11.10%	-25.94%	0.17%
Return on Invested Capital (ROIC)	―	-9.77%	-10.21%	-25.76%	0.16%
Return on Tangible Assets	―	4.05%	-5.70%	-48.67%	2.82%
Earnings Yield	―	2.52%	-6.20%	-30.73%	3.09%
Efficiency Ratios
Receivables Turnover	―	14.29	1.76	0.00	1.22
Payables Turnover	―	6.57	0.53	1.47	0.07
Inventory Turnover	―	1.43	0.07	1.79	<0.01
Fixed Asset Turnover	―	0.04	<0.01	0.00	<0.01
Asset Turnover	―	0.02	<0.01	0.00	<0.01
Working Capital Turnover Ratio	―	0.19	<0.01	0.00	<0.01
Cash Conversion Cycle	―	225.83	4.95K	-44.05	72.18K
Days of Sales Outstanding	―	25.55	207.43	0.00	299.33
Days of Inventory Outstanding	―	255.86	5.43K	203.47	76.85K
Days of Payables Outstanding	―	55.58	683.92	247.52	4.97K
Operating Cycle	―	281.41	5.63K	203.47	77.15K
Cash Flow Ratios
Operating Cash Flow Per Share	―	-904.22	-799.18	-763.90	-1.00K
Free Cash Flow Per Share	―	-1.58K	-1.26K	-1.90K	-2.09K
CapEx Per Share	―	677.20	465.78	1.13K	1.09K
Free Cash Flow to Operating Cash Flow	―	1.75	1.58	2.48	2.09
Dividend Paid and CapEx Coverage Ratio	―	-1.34	-1.72	-0.67	-0.92
Capital Expenditure Coverage Ratio	―	-1.34	-1.72	-0.67	-0.92
Operating Cash Flow Coverage Ratio	―	-0.38	-0.54	-10.80	-0.70
Operating Cash Flow to Sales Ratio	―	-3.80	-69.70	0.00	-372.43
Free Cash Flow Yield	―	-10.76%	-14.33%	-16.57%	-22.17%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	39.66	-16.12	-3.25	32.32
Price-to-Sales (P/S) Ratio	―	61.73	770.09	0.00	3.51K
Price-to-Book (P/B) Ratio	―	2.16	1.21	1.60	1.26
Price-to-Free Cash Flow (P/FCF) Ratio	―	-9.30	-6.98	-6.03	-4.51
Price-to-Operating Cash Flow Ratio	―	-16.26	-11.05	-14.99	-9.42
Price-to-Earnings Growth (PEG) Ratio	―	-0.24	0.06	>-0.01	-0.30
Price-to-Fair Value	―	2.16	1.21	1.60	1.26
Enterprise Value Multiple	―	27.38	-12.91	-2.05	50.32
Enterprise Value	―	912.21B	400.88B	423.70B	529.06B
EV to EBITDA	―	27.38	-12.91	-2.05	50.32
EV to Sales	―	63.75	581.77	0.00	3.27K
EV to Free Cash Flow	―	-9.60	-5.27	-3.72	-4.20
EV to Operating Cash Flow	―	-16.79	-8.35	-9.23	-8.78
Tangible Book Value Per Share	―	5.21K	6.35K	6.07K	7.11K
Shareholders’ Equity Per Share	―	6.80K	7.31K	7.15K	7.50K
Tax and Other Ratios
Effective Tax Rate	―	-0.06	>-0.01	>-0.01	-0.36
Revenue Per Share	―	238.12	11.47	0.00	2.69
Net Income Per Share	―	370.62	-547.81	-3.52K	292.35
Tax Burden	―	5.68	0.60	1.00	-8.38
Interest Burden	―	0.34	1.16	1.00	1.83
Research & Development to Revenue	―	1.33	34.01	0.00	252.80
SG&A to Revenue	―	1.65	65.95	0.00	-330.24
Stock-Based Compensation to Revenue	―	0.00	0.08	0.00	12.01
Income Quality	―	-2.44	0.87	0.22	21.08

Currency in KRW